(Q36291059)

13 August 2017

1 reference

title

Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia (English)

1 reference

13 August 2017

0 references

1 reference

Shapiro AD

1

1 reference

13 August 2017

Korth-Bradley J

series ordinal

2

1 reference

13 August 2017

Poon MC

series ordinal

3

1 reference

13 August 2017

publication date

1 November 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

11

1 reference

13 August 2017

issue

6

1 reference

13 August 2017

page(s)

571-582

1 reference

Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01149.X

Experience with a new percutaneous port system, Percuseal, for intravenous injection in patients with haemophilia, von Willebrand disease and severe alpha1-antitrypsin deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01149.X

NCOMP--a windows-based computer program for noncompartmental analysis of pharmacokinetic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01149.X

Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01149.X

Use of recombinant factor IX in subjects with haemophilia B undergoing surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01149.X

Efficacy and safety of monoclonal antibody purified factor IX concentrate in haemophilia B patients undergoing surgical procedures

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01149.X

Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01149.X

Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01149.X

The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01149.X

Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01149.X

Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01149.X

Continuous infusion of coagulation factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01149.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01149.X

Intermittent injections vs. continuous infusion of factor VIII in haemophilia patients undergoing major surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01149.X

Recombinant factor IX (BeneFix) by adjusted continuous infusion: a study of stability, sterility and clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01149.X

Continuous intravenous infusion of a plasma-derived factor IX concentrate (Mononine) in haemophilia B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2516.2005.01149.X

10.1111/J.1365-2516.2005.01149.X

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference